Learnings from the Earnings – Who’s Up? Who’s Down?

Calyxt

The Top Line. Cash, cash equivalents and restricted cash of $95.3M as of December 31, 2018. For the year ended December 31, 2018, they incurred losses from operations of $28.1 million and used net cash in operating activities of $20.3 million.

The Big Highlights. FDA consultation completed for High Oleic Soybean, first-ever gene-edited food product marketed in U.S. First sales of Calyxt High Oleic Soybean Oil, Calyno, and High Oleic Soybean Meal. Collaboration with Agtegra Cooperative to distribute Calyxt High Oleic Soybean. 48,000 acres contracted for 2019 growing season, more than double 2018 acres. Product pipeline advancing with High Fiber Wheat in line for next commercialization as early as 2022.

“2018 was a year of tremendous achievement for Calyxt. I am extremely proud to say that we received our first order for our premium High Oleic Soybean Oil, Calyno, with ~ 80% oleic acid content and zero grams of trans fat per serving. We believe this milestone welcomes a new era of food ingredients that are developed to help enhance the health profile of the consumer,” said Jim Blome, CEO of Calyxt. “Our strong relationships with our strategic partners are building the foundation of our farmer network and supply chain. Our recently announced alliance with Agtegra positions us for continued growth of our soybean franchise. Our growing customer base validates our innovative business model. Having more than doubled last year’s acres, we are on track for strong growth and we couldn’t be more excited about what the future holds for Calyxt.”

Check out more on the story here.